Evidence map›Paper›PMID 42419787›Full record

ArticleRMD open2026

Evaluation of pregnancy outcomes in patients with rheumatoid arthritis compared with the general population: results from a French national prospective and matched study.

Sabrina Hamroun, Grégoire Martin de Frémont, Nathalie Costedoat-Chalumeau, Marion Couderc, René-Marc Flipo, Laure Gossec, Christophe Richez, Rakiba Belkhir, Aline Frazier-Mironer, Valérie Devauchelle-Pensec and 15 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in RMD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Sabrina Hamroun *Rheumatology Department, NOVO Hospital, Pontoise, France.ORCID http://orcid.org/0000-0003-2721-1249
Grégoire Martin de Frémont *Rheumatology Department, Kremlin-Bicêtre University Hospital, Le Kremlin-Bicêtre, France.ORCID http://orcid.org/0000-0003-3393-3969
Nathalie Costedoat-ChalumeauUniversité Paris Cité and Université Sorbonne Paris Nord, INSERM, INRAE, Centre for Research in Epidemiology and Statistics, Paris, France.ORCID http://orcid.org/0000-0002-1555-9021
Marion CoudercRheumatology Department, Gabriel-Montpied Hospital, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.ORCID http://orcid.org/0000-0002-2001-1132
René-Marc FlipoRheumatology Department, Salengro Hospital, Lille University Hospital, Lille, France.ORCID http://orcid.org/0000-0001-5528-8070
Laure GossecINSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Université, Team Pepites, Paris, France.ORCID http://orcid.org/0000-0002-4528-310X
Christophe RichezRheumatology Department, CNRS, Immuno ConcEpT, UMR 5164, Bordeaux University Hospital, and University of Bordeaux, Bordeaux, France.ORCID http://orcid.org/0000-0002-3029-8739
Rakiba BelkhirRheumatology Department, Kremlin-Bicêtre University Hospital, Le Kremlin-Bicêtre, France.
Aline Frazier-MironerRheumatology Department, Lariboisière University Hospital, Paris, France.
Valérie Devauchelle-PensecRheumatology Department, Centre National de Référence des Maladies Auto-Immunes Rares du Nord-Ouest, CERAINOM, Brest University Hospital, Bres, France.
Hubert MarotteCHU Saint-Etienne, INSERM, Mines Saint Etienne, SAINBIOSE U1059, Université Jean Monnet, Service de Rhumatologie, Saint Etienne, France.ORCID http://orcid.org/0000-0003-1177-9497
Jérémie SellamRheumatology Department, CRSA Inserm UMRS8938, Sorbonne University, Saint-Antoine University Hospital, AP-HP centre, Paris, France.
Elisabeth GervaisRheumatology Department, University Hospital and LITEC UR15560 Poitiers, Poitiers, France.
Alban DerouxInternal Medicine Department, Grenoble University Hospital, Grenoble, France.
Cédric LukasRheumatology Department, Montpellier University Hospital, Montpellier, France.ORCID http://orcid.org/0000-0002-1095-3492
Emmanuelle DernisRheumatology Department, Le Mans Hospital, Le Mans, France.
Véronique Le GuernInternal Medicine Department, Referral Center for Rare Autoimmune and Systemic Diseases, Cochin Hospital, Paris, France.
Gaëlle Guettrot-ImbertInternal Medicine Department, Referral Center for Rare Autoimmune and Systemic Diseases, Cochin Hospital, Paris, France.
Nathalie LelongINSERM Obstetrical Perinatal and Pediatric Epidemiology Research Team, University of Paris, Paris, France.
Emmanuelle PannierPort-Royal Maternity Unit, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Paris, France.
Loïc SentilhesService de Gynécologie Obstétrique, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
Camille Le RayService de Gynécologie Obstétrique, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
Raphaèle Seror *Rheumatology Department, Kremlin-Bicêtre University Hospital, Le Kremlin-Bicêtre, France.ORCID http://orcid.org/0000-0002-5523-1856
Anna Moltó *Université Paris Cité and Université Sorbonne Paris Nord, INSERM, INRAE, Centre for Research in Epidemiology and Statistics, Paris, France anna.molto@aphp.fr.ORCID http://orcid.org/0000-0003-2246-1986
GR2 and the ENP2021 Study Groups

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe aim of the study was to assess the contemporary frequency of adverse pregnancy outcomes in women with rheumatoid arthritis (RA) and to identify associated factors.

methodsThis French prospective multicentre cohort included pregnant women with RA between 2015 and 2021. Maternal characteristics, disease activity, treatments and pregnancy outcomes were analysed. Outcomes of pregnancies in women with RA were compared in univariable analysis with those of matched general population women from the 2016 and 2021 French perinatal surveys assessing maternal and neonatal health. Multivariable logistic regressions were performed to identify factors associated with adverse outcomes.

resultsA total of 100 pregnancies in 90 women with RA were analysed. Mean maternal age was 33.7±5.0 years and 57.6% were nulliparous. During pregnancy, 46% received glucocorticoids and 39% biologic disease-modifying antirheumatic drugs. Compared with the 359 controls from the general population, preterm birth (OR 2.08, 95% CI 1.04 to 4.09) and small for gestational age (SGA) (OR

conclusionIn this contemporary cohort mostly followed in tertiary care centres, pregnancies in women with RA remained at increased risk of preterm birth and SGA. Exposure to systemic glucocorticoids at doses ≥10 mg/day emerged as a risk factor for preterm birth, although a contribution of maternal disease activity cannot be entirely excluded.

Indexed as

Arthritis, RheumatoidPregnancy ComplicationsPregnancy OutcomeAdultAntirheumatic AgentsFemaleFranceHumansInfant, NewbornInfant, Small for Gestational AgePregnancyPremature BirthProspective StudiesRisk FactorsAntirheumatic AgentsArthritis, RheumatoidAutoimmunityBiological TherapyEpidemiology

Identifiers

PMID42419787
PMCPMC13347905

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.